news and Updates


AureoGen closes a licensing agreement with Merck.

read more ....

Contact US

AureoGen Biosciences 
4717 Campus Drive Suite 2300 
Kalamazoo, MI 49008 

Mission Statement

Many successful drugs are natural products or derivatives of natural products. In contrast to synthetic compounds, natural products are not generated by chemical synthesis but instead isolated from microorganisms, such as bacteria and fungi. The cyclic peptides constitute an important group of natural product compounds. Drugs such as vancomycin, daptomycin, caspofungin, cyclosporin, and bleomycin all belong to this group and their successes in the clinic demonstrate that cyclic peptides can be antibacterials and antifungals, as well as immunosuppressive and even cancer drugs. 

AureoGen’s therapeutic focus is on antibiotics and the company’s mission is to utilize state-of-the-art chemistry and genetic engineering methodologies to generate novel drug candidates from existing cyclic peptide templates.

About Us

AureoGen Biosciences was incorporated on August 12, 2003. The company’s business is focused on the development of novel chemistry and genetic engineering methodologies for the modification of cyclic peptide-based compounds. Historically, structural modifications required to convert a native cyclic peptide into a functional drug often involved complicated and expensive synthetic chemistry approaches. This hampered the development of many promising drug candidates. It also prevented optimization (such as reduction of side effects) of many existing drugs. AureoGen is taking advantage of recent advances in medicinal chemistry to develop novel approaches that allow efficient, cost-effective modification, optimization, and production of cyclic peptide compounds. AureoGen’s chemistries allow many modifications (to cyclic peptides) to be introduced directly, without the need for the multiple synthesis steps, disassembly of the core ring structure, and re-synthesis of large portions of the molecule, that characterized older approaches. Similarly, advances in biology and genetics have produced tools and knowledge that allow efficient structural modification of cyclic peptides by (genetic) engineering of the non-ribosomal peptide synthase (NRPS) complexes responsible for their synthesis in the producer organisms. Thus, using state-of-the-art chemical and genetic engineering methodologies, AureoGen is producing novel cyclic peptide-based drug candidates that are new chemical entities (NCEs) and that have the pharmacological properties required for development into useful therapeutics. AureoGen’s methodologies allow for the efficient and cost-effective in-depth exploration of the pharmacological properties (structure activity relationships, SAR) of virtually any cyclic peptide, as well as simple and economical generation of entirely novel cyclic peptides.